NCT02558894
Clinical Trial Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02558894
Title Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors NCT02558894
Indications
pancreatic ductal carcinoma
Therapies
Durvalumab
Tremelimumab
Age Groups: adult
Covered Countries USA | NLD | ESP | DEU | CAN

Facility Status City State Zip Country Details
Research Site Tampa Florida 33612 United States Details
Research Site New York New York 10065 United States Details
Research Site Vancouver British Columbia V5Z 4E6 Canada Details
Research Site Oshawa Ontario L1G 2B9 Canada Details
Research Site Ottawa Ontario K1H 8L6 Canada Details
Research Site Toronto Ontario M4N 3M5 Canada Details
Research Site Toronto Ontario M5G 2M9 Canada Details
Research Site Montreal Quebec H4A 3T2 Canada Details
Research Site Friedrichshafen 88045 Germany Details
Research Site München 81377 Germany Details
Research Site Tübingen 72076 Germany Details
Research Site Amsterdam 1105 AZ Netherlands Details
Research Site Groningen 9713 GZ Netherlands Details
Research Site Nijmegen 6525 GA Netherlands Details
Research Site Seongnam-si 463-707 South Korea Details
Research Site Seoul 03080 South Korea Details
Research Site Seoul 03722 South Korea Details
Research Site Seoul 06591 South Korea Details
Research Site Seoul 135-710 South Korea Details
Research Site Barcelona 08035 Spain Details
Research Site Madrid 28034 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field